Newtownabbey, United Kingdom

Keiran Logan

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: University of Ulster. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Sonodynamic Therapy by Keiran Logan

Introduction

Keiran Logan is an accomplished inventor based in Newtownabbey, Antrim, GB. He has made significant contributions to the field of medical technology, particularly in the area of cancer treatment. His innovative approach focuses on enhancing therapeutic methods through the use of advanced microbubble complexes.

Latest Patents

Keiran Logan holds a patent for his invention related to sonodynamic therapy. This invention involves microbubble complexes designed for use in methods of sonodynamic therapy. These complexes consist of a microbubble that is attached to or associated with one or more linking groups. Each linking group is bound to at least one sonosensitizing agent and at least one chemotherapeutic agent. This invention is particularly suitable for treating deep-sited tumors, especially pancreatic cancer.

Career Highlights

Keiran Logan is affiliated with the University of Ulster, where he continues to advance his research and development in medical technologies. His work has garnered attention for its potential to improve treatment outcomes for patients with challenging cancers.

Collaborations

Keiran has collaborated with notable colleagues, including John Francis Callan and Anthony McHale. Their combined expertise contributes to the innovative research being conducted at the University of Ulster.

Conclusion

Keiran Logan's work in sonodynamic therapy represents a significant advancement in cancer treatment methodologies. His innovative microbubble complexes hold promise for improving therapeutic efficacy against deep-sited tumors.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…